Clarification of Attana's information policy
Attana wants to clarify what information the company shares when receiving orders on instruments. The basic principle is that instrument orders are part of Attana’s day-to-day operations, thus details regarding specific orders, such as order size or customer, are generally not disclosed.
The company works according to an established information policy and the board always makes an assessment before publishing information to decide whether and what information the company should publish to the market. In general, the company does not disclose details about specific instrument orders, however the board always assesses whether or not to disclose detailed information by evaluating, among other things, the cash flow impact, the character of the customer and the size of the order.
For more information, please contact:
Teodor Aastrup, CEO
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact email@example.com